Latest Software News

EPX Limited reports robust FY25 growth with a 10% rise in Annual Contract Value and a 35% increase in site numbers, driven by strategic sales restructuring and key new partnerships.

xReality Group has secured a $2.1 million grant from the Australian Government to fast-track AI enhancements in its Operator XR tactical training platform, aiming to solidify its leadership in law enforcement and defense training worldwide.

xReality Group’s US subsidiary Operator XR has landed its largest order yet, a $5.7 million contract to supply VR training systems to the Texas Department of Public Safety, marking a significant milestone in its US expansion.

Prophecy International and Complexica announce a strategic merger to form MergeCo, an ASX-listed AI pure play with enhanced scale, product synergies, and growth potential.

Prophecy International Holdings has agreed to acquire Complexica in a transformative merger, creating Complexica Group Limited, an ASX-listed AI pure play software company with enhanced scale and growth potential.

Nanosonics has secured FDA clearance for its next-generation trophon3 device and trophon2 Plus software upgrade, setting the stage for significant growth in the US medical disinfection market.

Infomedia Limited has struck a deal with TPG Capital Asia to be acquired at $1.72 per share, offering shareholders a 41% premium over recent trading prices. The scheme includes fully franked dividends, potentially raising the effective value to $1.74 per share for eligible investors.

Nanoveu Limited advances its proprietary 16nm ECS-DoT chip fabrication, targeting completion by Q4 2025, supported by a strategic partnership and expanded engineering teams across multiple continents.

Orcoda Limited has clarified the materiality and timing of disclosures related to its ACTA trial and new SaaS contracts, confirming compliance with ASX Listing Rules and explaining the rationale behind its announcements.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.